A phase III trial of glofitamab plus gemcitabine and oxaliplatin (gemox) vs rituximab plus gemox for relapsed/refractory diffuse large B-cell lymphoma

Mark S. Hertzberg, Matthew Ku, Olivier Catalani, Betsy Althaus, Steven Simko, Gareth Peter Gregory

Research output: Contribution to journalMeeting AbstractOtherpeer-review

Original languageEnglish
Article number253
Pages (from-to)344-345
Number of pages2
JournalHematological Oncology
Volume39
Issue numberSupp 2
Publication statusPublished - Jun 2021
EventInternational Conference on Malignant Lymphoma 2021 - Virtual, Lugano, Switzerland
Duration: 18 Jun 202121 Jun 2021
Conference number: 16th
https://www.icml.ch/icml/16th-icml-redirect/general-information.html

Cite this